Journal of International Oncology››2023,Vol. 50››Issue (3): 138-143.doi:10.3760/cma.j.cn371439-20221214-00028
• Original Articles •Previous ArticlesNext Articles
Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun()
Received:
2022-12-14Revised:
2023-01-18Online:
2023-03-08Published:
2023-04-12Contact:
Xu Jiankun, Email:
Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun. Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases[J]. Journal of International Oncology, 2023, 50(3): 138-143.
"
基线特征 | 例数(%) |
---|---|
性别 | |
男 | 14(66.67) |
女 | 7(33.33) |
年龄(岁) | |
>60 | 12(57.14) |
≤60 | 9(42.86) |
原发肿瘤 | |
非小细胞肺癌 | 12(57.14) |
小细胞肺癌 | 1(4.76) |
乳腺癌 | 3(14.30) |
直肠癌 | 2(9.52) |
肾癌 | 2(9.52) |
卵巢癌 | 1(4.76) |
基线特征 | 例数(%) |
原发灶病理类型 | |
腺癌 | 11(52.38) |
鳞状细胞癌 | 4(19.04) |
浸润性导管癌 | 3(14.30) |
透明细胞癌 | 2(9.52) |
小细胞癌 | 1(4.76) |
病灶个数 | |
1 | 12(57.14) |
2~4 | 7(33.33) |
5~10 | 2(9.52) |
病灶最大直径(cm) | |
<2 | 16(76.19) |
2~3 | 5(23.81) |
病灶最大体积(cm3) | |
<4 | 14(66.67) |
4~6 | 7(33.33) |
DS-GPA评分(分) | |
≤2 | 10(47.62) |
>2 | 11(52.38) |
全身治疗 | |
是 | 16(76.19) |
否 | 5(23.81) |
[1] | Lamba N, Wen PY, Aizer AA. Epidemiology of brain metastases and leptomeningeal disease[J]. Neuro Oncol, 2021, 23(9): 1447-1456. DOI: 10.1093/neuonc/noab101. doi:10.1093/neuonc/noab101 |
[2] | Garsa A, Jang JK, Baxi S, et al. Radiation therapy for brain metastases: a systematic review[J]. Pract Radiat Oncol, 2021, 11(5): 354-365. DOI: 10.1016/j.prro.2021.04.002. doi:10.1016/j.prro.2021.04.002pmid:34119447 |
[3] | July J, Pranata R. Hypofractionated versus single-fraction stereotactic radiosurgery for the treatment of brain metastases: a systematic review and meta-analysis[J]. Clin Neurol Neurosurg, 2021, 206: 106645. DOI: 10.1016/j.clineuro.2021.106645. doi:10.1016/j.clineuro.2021.106645 |
[4] | Masucci GL. Hypofractionated radiation therapy for large brain metastases[J]. Front Oncol, 2018, 8: 379. DOI: 10.3389/fonc.2018.00379. doi:10.3389/fonc.2018.00379pmid:30333955 |
[5] | Sarmey N, Kaisman-Elbaz T, Mohammadi AM. Management strategies for large brain metastases[J]. Front Oncol, 2022, 12: 827304. DOI: 10.3389/fonc.2022.827304. doi:10.3389/fonc.2022.827304 |
[6] | Tonse R, Tom MC, Mehta MP, et al. Integration of systemic therapy and stereotactic radiosurgery for brain metastases[J]. Cancers (Basel), 2021, 13(15): 3682. DOI: 10.3390/cancers13153682. doi:10.3390/cancers13153682 |
[7] | Lupattelli M, Tini P, Nardone V, et al. Stereotactic radiotherapy for brain oligometastases[J]. Rep Pract Oncol Radiother, 2022, 27(1): 15-22. DOI: 10.5603/RPOR.a2021.0133. doi:10.5603/RPOR.a2021.0133 |
[8] | 周冲, 郭汝元, 夏铀铀, 等. 基于直线加速器的分次立体定向放疗在脑寡转移肿瘤中的应用[J]. 肿瘤研究与临床, 2020, 32(11): 741-744. DOI: 10.3760/cma.j.cn115355-20200401-00166. doi:10.3760/cma.j.cn115355-20200401-00166 |
[9] | 中国放射性脑损伤多学科协作组; 中国医师协会神经内科分会脑与脊髓损害专业委员会. 放射性脑损伤诊治中国专家共识[J]. 中华神经医学杂志, 2019, 18(6): 541-549. DOI: 10.3760/cma.j.issn.1671-8925.2019.06.001. doi:10.3760/cma.j.issn.1671-8925.2019.06.001 |
[10] | Mohammadi AM, Schroeder JL, Angelov L, et al. Impact of the radiosurgery prescription dose on the local control of small (2 cm or smaller) brain metastases[J]. J Neurosurg, 2017, 126(3): 735-743. DOI: 10.3171/2016.3.JNS153014. doi:10.3171/2016.3.JNS153014pmid:27231978 |
[11] | Baschnagel AM, Meyer KD, Chen PY, et al. Tumor volume as a predictor of survival and local control in patients with brain metastases treated with Gamma Knife surgery[J]. J Neurosurg, 2013, 119(5): 1139-1144. DOI: 10.3171/2013.7.JNS13431. doi:10.3171/2013.7.JNS13431pmid:23971958 |
[12] | Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline[J]. J Clin Oncol, 2022, 40(5): 492-516. DOI: 10.1200/JCO.21.02314. doi:10.1200/JCO.21.02314 |
[13] | Gondi V, Bauman G, Bradfield L, et al. Radiation therapy for brain metastases: an ASTRO clinical practice guideline[J]. Pract Radiat Oncol, 2022, 12(4): 265-282. DOI: 10.1016/j.prro.2022.02.003. doi:10.1016/j.prro.2022.02.003pmid:35534352 |
[14] | Remick JS, Kowalski E, Khairnar R, et al. A multi-center analysis of single-fraction versus hypofractionated stereotactic radiosurgery for the treatment of brain metastasis[J]. Radiat Oncol, 2020, 15(1): 128. DOI: 10.1186/s13014-020-01522-6. doi:10.1186/s13014-020-01522-6pmid:32466775 |
[15] | Zhou C, Xia Y, Huang P, et al. Fractionated stereotactic radiation therapy using volumetric modulated arc therapy in patients with solitary brain metastases[J]. Biomed Res Int, 2020, 2020: 6342057. DOI: 10.1155/2020/6342057. doi:10.1155/2020/6342057 |
[16] | Myrehaug S, Hudson J, Soliman H, et al. Hypofractionated stereotactic radiation therapy for intact brain metastases in 5 daily fractions: effect of dose on treatment response[J]. Int J Radiat Oncol Biol Phys, 2022, 112(2): 342-350. DOI: 10.1016/j.ijrobp.2021.09.003. doi:10.1016/j.ijrobp.2021.09.003 |
[17] | Milano MT, Grimm J, Niemierko A, et al. Single- and multifraction stereotactic radiosurgery dose/volume tolerances of the brain[J]. Int J Radiat Oncol Biol Phys, 2021, 110(1): 68-86. DOI: 10.1016/j.ijrobp.2020.08.013. doi:10.1016/j.ijrobp.2020.08.013 |
[18] | Lehrer EJ, Peterson JL, Zaorsky NG, et al. Single versus multifraction stereotactic radiosurgery for large brain metastases: an international meta-analysis of 24 trials[J]. Int J Radiat Oncol Biol Phys, 2019, 103(3): 618-630. DOI: 10.1016/j.ijrobp.2018.10.038. doi:10.1016/j.ijrobp.2018.10.038 |
[19] | Andruska N, Kennedy WR, Bonestroo L, et al. Dosimetric predictors of symptomatic radiation necrosis after five-fraction radiosurgery for brain metastases[J]. Radiother Oncol, 2021, 156: 181-187. DOI: 10.1016/j.radonc.2020.12.011. doi:10.1016/j.radonc.2020.12.011 |
[20] | Yan M, Holden L, Wang M, et al. Gamma knife icon based hypofractionated stereotactic radiosurgery (GKI-HSRS) for brain metastases: impact of dose and volume[J]. J Neurooncol, 2022, 159(3): 705-712. DOI: 10.1007/s11060-022-04115-3. doi:10.1007/s11060-022-04115-3 |
[1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156. |
[4] | Lyu Lu, Sun Pengfei.Gut flora and cervical cancer[J]. Journal of International Oncology, 2023, 50(6): 373-376. |
[5] | Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association.Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy (2023 version)[J]. Journal of International Oncology, 2023, 50(4): 193-201. |
[6] | Gong Heyi, Yi Yan, Zhang Jian, Li Baosheng.Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy[J]. Journal of International Oncology, 2023, 50(12): 745-750. |
[7] | Ma Xueyan, Lu Lili, Sun Pengfei.Advances in the immune microenvironment in cervical cancer[J]. Journal of International Oncology, 2023, 50(1): 47-50. |
[8] | Li Zhilei, Luo Jialin.Biological indexes for predicting sensitivity of preoperative concurrent chemoradiotherapy for locally advanced rectal cancer[J]. Journal of International Oncology, 2022, 49(9): 564-567. |
[9] | Wu Puyuan, Qi Liang, Wang Tao, Shi Minke, Sun Yuwei, Wang Lifeng, Liu Baorui, Yan Jing, Ren Wei.Efficacy of postoperative radiotherapy based on modified clinical target volume according to high-frequency recurrence regions in patients with esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2022, 49(8): 464-472. |
[10] | Xia Lingling, Chen Yongshun, Li Bin, Ning Tingting, Zhang Caiyutian.Comparison of safety and efficacy between chemoradiotherapy and chemotherapy after R0 resection in pN+esophageal squamous cell carcinoma patients[J]. Journal of International Oncology, 2022, 49(6): 334-339. |
[11] | Xiao Nan, Sun Pengfei.Research progress of oxidative stress in the sensitivity of chemoradiotherapy for gliomas[J]. Journal of International Oncology, 2022, 49(6): 357-361. |
[12] | Ye Qian, Ling Zhi, Liu Shenxiang, Lu Guotao, Yin Xudong.Effects of sarcopenia on the clinical efficacy and prognosis of radical radiotherapy in elderly patients with esophageal cancer[J]. Journal of International Oncology, 2022, 49(4): 199-205. |
[13] | Sun Xiaolin, Zhang Zhanyu, Xu Linzong, Liu Yingchao, Li Xiaomei.Potential value of radiotherapy combined with immunotherapy in breast cancer brain metastases[J]. Journal of International Oncology, 2022, 49(4): 243-246. |
[14] | Huang Huayu, Song Qibin, Gong Hongyun, Song Jia.Analysis on the incidence and risk factors of pneumonia in patients with lung cancer receiving thoracic radiotherapy and immunotherapy[J]. Journal of International Oncology, 2022, 49(12): 718-723. |
[15] | Kong Chunyu, Sun Pengfei.SLC7A11 and glioma[J]. Journal of International Oncology, 2022, 49(10): 604-607. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||